How many papillae in conventional papillary carcinoma? A clinical evidence-based pathology study of 235 unifocal encapsulated papillary thyroid carcinomas, with emphasis on the diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features Journal Article


Authors: Xu, B.; Serrette, R.; Tuttle, R. M.; Alzumaili, B.; Ganly, I.; Katabi, N.; Tallini, G.; Ghossein, R.
Article Title: How many papillae in conventional papillary carcinoma? A clinical evidence-based pathology study of 235 unifocal encapsulated papillary thyroid carcinomas, with emphasis on the diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features
Abstract: Background: The percentage of papillae is a crucial criterion in differentiating noninvasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) from papillary thyroid carcinomas (PTCs) and in sub-classifying PTC into classic and follicular variant. Since the description of NIFTP, three studies have shown that the presence of any papillae may be associated with nodal metastasis, which led to modification of the NIFTP criterion from <1% papillae to no true papillae allowed. We aim at providing clinical evidence-based data on the impact that papillary growth has on nodal spread and tumor genotype in tumors previously diagnosed as encapsulated unifocal PTC. Methods: A meticulous histopathologic examination was performed on 235 cases previously diagnosed as unifocal encapsulated PTC (U-EPTC). One hundred of these cases were subjected to BRAFV600E and NRASQ61R immunohistochemistry. Results: In our cohort, 27 patients (12%) had lymph node metastasis (N1) at the time of initial resection. Overall, 89% of the tumors in the N1 group contained ≥50% papillae, compared with 13% in the N0/Nx group. Nodal metastases were only present in tumors with ≥1% papillae. In noninvasive U-EPTC (n = 161), N1 disease was seen only in tumors with ≥10% papillae. A higher percentage of papillae within the tumor also correlated with an increased frequency of BRAFV600E and decreased rate of NRASQ61R. None of the 26 NRAS-positive cases had nodal disease, including the invasive tumors. Among 216 patients with follow-up (median: 5.2 years), 3 patients (1.5%) had distant metastases, all detected at the initial presentation. All three tumors displayed 100% follicular growth, and capsular or vascular invasion. There was no locoregional recurrence in the entire cohort. Conclusion: In U-EPTC, there is a strong correlation between high percentage of papillary growth, presence of nodal metastasis, and BRAF+/RAS- genotype regardless of invasive status. Nodal metastases were not seen in tumors with <1% papillae irrespective of invasive status. These findings indicate that the initial criterion of <1% papillae is still valid for the diagnosis of NIFTP. Reinstituting this criterion will spare a carcinoma diagnosis and unnecessary therapy with its side effects on patients who have negligible clinical risk. © Mary Ann Liebert, Inc.
Keywords: immunohistochemistry; adolescent; adult; child; aged; major clinical study; histopathology; follow up; lymph node metastasis; cancer diagnosis; tumor volume; cohort analysis; genotype; distant metastasis; ras protein; cancer classification; thyroid papillary carcinoma; b raf kinase; papillary; thyroid follicular carcinoma; adverse event; oncogene n ras; genotype phenotype correlation; clinical outcome; follicular; papillary thyroid carcinoma; human; male; female; priority journal; article; encapsulated variant; noninvasive follicular thyroid neoplasm with papillary like nuclear feature
Journal Title: Thyroid
Volume: 29
Issue: 12
ISSN: 1050-7256
Publisher: Mary Ann Liebert, Inc  
Date Published: 2019-12-16
Start Page: 1792
End Page: 1803
Language: English
DOI: 10.1089/thy.2019.0328
PUBMED: 31452453
PROVIDER: scopus
PMCID: PMC6918873
DOI/URL:
Notes: Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Ronald A Ghossein
    482 Ghossein
  2. Robert M Tuttle
    481 Tuttle
  3. Nora Katabi
    303 Katabi
  4. Ian Ganly
    430 Ganly
  5. Bin   Xu
    227 Xu